From UM Labs to Abivax: The Remarkable Journey of the Drug That Sought to Conquer Chronic Intestinal Diseases

The collaboration between the laboratories at the University of Montpellier (UM) and Abivax has led to the development of the drug Obefazimod: the result of nearly twenty years of R&D, this compound could revolutionize the treatment of chronic intestinal diseases. This is a success on both a national and international scale, the result of collaboration between Montpellier-based researchers and an innovative company.

Read the full article: From UM Labs to Abivax: The Remarkable Journey of the Drug That Sought to Conquer Chronic Intestinal Diseases